Didier Laureillard

Low-level of mitochondrial DNA alterations during direct-acting antiviral treatment in leukocytes of people who inject drugs living with HCV

Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, offering high cure rates and favorable safety profiles. However, concerns remain regarding their long-term mitochondrial safety, particularly among vulnerable populations such as people who inj...